Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors
Journal of Nuclear Medicine. 2014-09-04; 55(10): 1650-1657
DOI: 10.2967/jnumed.114.142000
Lire sur PubMed
1. J Nucl Med. 2014 Oct;55(10):1650-7. doi: 10.2967/jnumed.114.142000. Epub 2014 Sep
4.
Targeting neuropeptide receptors for cancer imaging and therapy: perspectives
with bombesin, neurotensin, and neuropeptide-Y receptors.
Morgat C(1), Mishra AK(2), Varshney R(3), Allard M(4), Fernandez P(5), Hindié
E(1).
Author information:
(1)CHU de Bordeaux, Service de Médecine Nucléaire, Bordeaux, France University of
Bordeaux, INCIA, UMR 5287, Talence, France CNRS, INCIA, UMR 5287, Talence, France
.
(2)University of Bordeaux, INCIA, UMR 5287, Talence, France CNRS, INCIA, UMR
5287, Talence, France Division of Cyclotron and Radiopharmaceutical Sciences,
Institute of Nuclear Medicine and Allied Sciences, DRDO, New Delhi, India; and.
(3)Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear
Medicine and Allied Sciences, DRDO, New Delhi, India; and.
(4)CHU de Bordeaux, Service de Médecine Nucléaire, Bordeaux, France University of
Bordeaux, INCIA, UMR 5287, Talence, France EPHE, Bordeaux, France.
(5)CHU de Bordeaux, Service de Médecine Nucléaire, Bordeaux, France University of
Bordeaux, INCIA, UMR 5287, Talence, France CNRS, INCIA, UMR 5287, Talence,
France.
Receptors for some regulatory peptides are highly expressed in tumors. Selective
radiolabeled peptides can bind with high affinity and specificity to these
receptors and exhibit favorable pharmacologic and pharmacokinetic properties,
making them suitable agents for imaging or targeted therapy. The success
encountered with radiolabeled somatostatin analogs is probably the first of a
long list, as multiple peptide receptors are now recognized as potential targets.
This review focuses on 3 neuropeptide receptor systems (bombesin, neurotensin,
and neuropeptide-Y) that offer high potential in the field of nuclear oncology.
The underlying biology of these peptide/receptor systems, their physiologic and
pathologic roles, and their differential distribution in normal and tumoral
tissues are described with emphasis on breast, prostate, and lung cancers.
Radiolabeled analogs that selectively target these receptors are highlighted.
© 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
DOI: 10.2967/jnumed.114.142000
PMID: 25189338 [Indexed for MEDLINE]